Report
Jacob Mekhael

Onward Medical 1H25 update shows ARC-EX launch on track, home use label by YE25

Onward reported 1H25 results demonstrating positive execution with the company achieving its internal target of selling 30 devices as part of the planned phased launch of the ARC-EX device in the US. We are encouraged to learn that the company expects continued demand for the remainder of the year to meet its FY25 targets (KBCSe: 193 devices). Timelines were reiterated, and we look forward to the home use label expected by YE25, which we view as an important driver for broader commercial uptake of ARC-EX, while the pivotal Empower BP trial of the implantable ARC-IM system continues to expect the first patient enrolment by YE25. With a cash position of € 40.9m, we expect Onward to have a cash runway into 2H26 (KBCSe), and reiterate our € 10.4 TP and BUY rating.
Underlying
ONWARD MEDICAL NV

Provider
KBC Securities
KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

 

Analysts
Jacob Mekhael

Other Reports on these Companies
Other Reports from KBC Securities

ResearchPool Subscriptions

Get the most out of your insights

Get in touch